Cargando…

Analysis of tigecycline resistance development in clinical Acinetobacter baumannii isolates through a combined genomic and transcriptomic approach

Tigecycline (Tgc) is considered a last-resort antibiotic for the treatment of multi-drug resistant bacteria. To study Tgc resistance development in the important nosocomial pathogen Acinetobacter baumannii, we adopted six clinical isolates from three patients undergoing antibiotic treatment, and bac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Lin, Cui, Yujun, Zheng, Beiwen, Jiang, Saiping, Yu, Wei, Shen, Ping, Ji, Jinru, Li, Lanjuan, Qin, Nan, Xiao, Yonghong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886253/ https://www.ncbi.nlm.nih.gov/pubmed/27240484 http://dx.doi.org/10.1038/srep26930

Ejemplares similares

Comparative Genomic Analysis of 19 Clinical Isolates of Tigecycline-Resistant Acinetobacter baumannii
por: Liu, Lin, et al.
Publicado: (2020)

The Transcriptomic Signature of Tigecycline in Acinetobacter baumannii
por: Li, Liping, et al.
Publicado: (2020)

Resistance mechanisms of tigecycline in Acinetobacter baumannii
por: Sun, Chunli, et al.
Publicado: (2023)

Tigecycline Heteroresistance and Resistance Mechanism in Clinical Isolates of Acinetobacter baumannii
por: Jo, Jeongwoo, et al.
Publicado: (2021)

Genomic and Phenotypic Evolution of Tigecycline-Resistant Acinetobacter baumannii in Critically Ill Patients
por: Zhang, Jiangang, et al.
Publicado: (2022)

Genome sequencing and genomic characterization of a tigecycline-resistant Klebsiella pneumoniae strain isolated from the bile samples of a cholangiocarcinoma patient
por: Zheng, Beiwen, et al.
Publicado: (2014)

Multiple heteroresistance to tigecycline and colistin in Acinetobacter baumannii isolates and its implications for combined antibiotic treatment
por: Jo, Jeongwoo, et al.
Publicado: (2023)

The Mechanism of Tigecycline Resistance in Acinetobacter baumannii Revealed by Proteomic and Genomic Analysis
por: Liu, Cunwei, et al.
Publicado: (2023)

Role of efflux pumps in reduced susceptibility to tigecycline in Acinetobacter baumannii
por: Ardehali, S.H., et al.
Publicado: (2019)

Role of Efflux Pumps in Reduced Susceptibility to Tigecycline among Clinical Isolates of Acinetobacter baumannii
por: Mahapatra, Ashoka, et al.
Publicado: (2022)

Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii
por: Niu, Tianshui, et al.
Publicado: (2019)

In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii
por: Principe, Luigi, et al.
Publicado: (2009)

Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii
por: Madadi-Goli, Nahid, et al.
Publicado: (2017)

Synergistic Antibacterial Effect of Casein-AgNPs Combined with Tigecycline against Acinetobacter baumannii
por: Chen, Yu-Hsuan, et al.
Publicado: (2021)

Effects of colistin and tigecycline on multidrug-resistant Acinetobacter baumannii biofilms: advantages and disadvantages of their combination
por: Sato, Yoshinori, et al.
Publicado: (2021)

In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant Acinetobacter baumannii
por: Abdul-Mutakabbir, Jacinda C., et al.
Publicado: (2021)

Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem-resistant Acinetobacter baumannii bloodstream infections: cefoperazone–sulbactam associated with resistance and tigecycline increased the mortality
por: Niu, Tianshui, et al.
Publicado: (2018)

Clinical Outcomes of Tigecycline in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection
por: Shin, Jung Ar, et al.
Publicado: (2012)

Effects of In vivo Emergent Tigecycline Resistance on the Pathogenic Potential of Acinetobacter baumannii
por: Hornsey, Michael, et al.
Publicado: (2018)

COMPARISON OF TWO DIFFERENT METHODS FOR TIGECYCLINE SUSCEPTIBILITY TESTING IN ACINETOBACTER BAUMANNII
por: Bedenić, Branka, et al.
Publicado: (2018)

Characterization of Increased Extracellular Vesicle-Mediated Tigecycline Resistance in Acinetobacter baumannii
por: Cho, Hyejin, et al.
Publicado: (2023)

Evaluation of the synergistic effect of a combination of colistin and tigecycline against multidrug-resistant Acinetobacter baumannii
por: Kaya, Ilkem Acar, et al.
Publicado: (2017)

Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia
por: Deng, Yanling, et al.
Publicado: (2022)

In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy
por: Mezzatesta, Maria Lina, et al.
Publicado: (2008)

Confronting Tigecycline-Resistant Acinetobacter baumannii via Immunization Against Conserved Resistance Determinants
por: Chiang, Ming-Hsien, et al.
Publicado: (2020)

Delirium induced by tigecycline treatment for Acinetobacter baumannii infection: A case report
por: Zheng, Xiaoying, et al.
Publicado: (2019)

Tigecycline Versus Colistin in the Treatment of Carbapenem-resistant Acinetobacter baumannii Complex Osteomyelitis
por: Oliveira, Priscila R., et al.
Publicado: (2020)

Alteration of adeS Contributes to Tigecycline Resistance and Collateral Sensitivity to Sulbactam in Acinetobacter baumannii
por: Yang, Yunxing, et al.
Publicado: (2023)

In vitro Comparison of Anti-Biofilm Effects against Carbapenem-Resistant Acinetobacter baumannii: Imipenem, Colistin, Tigecycline, Rifampicin and Combinations
por: Song, Joon Young, et al.
Publicado: (2015)

Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex
por: Ye, Jung-Jr, et al.
Publicado: (2016)

Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii
por: Zhou, Yangang, et al.
Publicado: (2019)

Severe infective endocarditis with systemic embolism due to community associated methicillin-resistant Staphylococcus aureus ST630
por: Zheng, Beiwen, et al.
Publicado: (2014)

In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa
por: Ahmed, Nahid H, et al.
Publicado: (2012)

In Vitro Activity of Tigecycline and Colistin against clinical isolates of Acinetobacter baumannii in Hospitals in Tehran and Bandar-Abbas, Iran
por: peerayeh, Shahin najar, et al.
Publicado: (2014)

In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia
por: Cikman, Aytekin, et al.
Publicado: (2015)

In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii
por: Park, Gyun Cheol, et al.
Publicado: (2016)

Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii
por: Chang, Kang, et al.
Publicado: (2022)

In-Vitro Activity of Polymyxin B, Rifampicin, Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii in Singapore
por: Lim, Tze-Peng, et al.
Publicado: (2011)

Combination Treatment with Intravenous Tigecycline and Intraventricular and Intravenous Colistin in Postoperative Ventriculitis Caused by Multidrug-resistant Acinetobacter baumannii
por: Mizrahi, Cezar J, et al.
Publicado: (2019)

Fitness Costs of Tigecycline Resistance in Acinetobacter baumannii and the Resistance Mechanism Revealed by a Transposon Mutation Library
por: Wang, Ping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uvb6upvns392ap6q1m0s6onn80